A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

BACKGROUND: Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and safety of hetrombopag in ITP patients. METHO...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Hematol Oncol
Autors principals: Mei, Heng, Liu, Xiaofan, Li, Yan, Zhou, Hu, Feng, Ying, Gao, Guangxun, Cheng, Peng, Huang, Ruibin, Yang, Linhua, Hu, Jianda, Hou, Ming, Yao, Yazhou, Liu, Li, Wang, Yi, Wu, Depei, Zhang, Liansheng, Zheng, Changcheng, Shen, Xuliang, Hu, Qi, Liu, Jing, Jin, Jie, Luo, Jianmin, Zeng, Yun, Gao, Sujun, Zhang, Xiaohui, Zhou, Xin, Shi, Qingzhi, Xia, Ruixiang, Xie, Xiaobao, Jiang, Zhongxing, Gao, Li, Bai, Yuansong, Xiong, Junye, Li, Runzi, Zou, Jianjun, Niu, Ting, Yang, Renchi, Hu, Yu
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7905908/
https://ncbi.nlm.nih.gov/pubmed/33632264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01047-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars